BACKGROUND AND PURPOSE: Because of its association with atrial fibrillation and heart failure, we hypothesized that amino terminal pro-B-type natriuretic peptide (NT-proBNP) would identify a subgroup of patients from the Warfarin-Aspirin Recurrent Stroke Study, diagnosed with inferred noncardioembolic ischemic strokes, where anticoagulation would be more effective than antiplatelet agents in reducing risk of subsequent events. METHODS:NT-proBNP was measured in stored serum collected at baseline from participants enrolled in Warfarin-Aspirin Recurrent Stroke Study, a previously reported randomized trial. Relative effectiveness of warfarin and aspirin in preventing recurrent ischemic stroke or death over 2 years was compared based on NT-proBNP concentrations. RESULTS: About 95% of 1028 patients with assays had NT-proBNP below 750 pg/mL, and among them, no evidence for treatment effect modification was evident. For 49 patients with NT-proBNP >750 pg/mL, the 2-year rate of events per 100 person-years was 45.9 for the aspirin group and 16.6 for the warfarin group, whereas for 979 patients with NT-proBNP ≤750 pg/mL, rates were similar for both treatments. For those with NT-proBNP >750 pg/mL, the hazard ratio was 0.30 (95% confidence interval: 0.12-0.84; P=0.021) significantly favoring warfarin over aspirin. A formal test for interaction of NT-proBNP with treatment was significant (P=0.01). CONCLUSIONS: For secondary stroke prevention, elevated NT-proBNP concentrations may identify a subgroup of ischemic stroke patients without known atrial fibrillation, about 5% based on the current study, who may benefit more from anticoagulants than antiplatelet agents. Clinical Trial Registration- This trial was not registered because enrollment began before 2005.
RCT Entities:
BACKGROUND AND PURPOSE: Because of its association with atrial fibrillation and heart failure, we hypothesized that amino terminal pro-B-type natriuretic peptide (NT-proBNP) would identify a subgroup of patients from the Warfarin-Aspirin Recurrent Stroke Study, diagnosed with inferred noncardioembolic ischemic strokes, where anticoagulation would be more effective than antiplatelet agents in reducing risk of subsequent events. METHODS: NT-proBNP was measured in stored serum collected at baseline from participants enrolled in Warfarin-Aspirin Recurrent Stroke Study, a previously reported randomized trial. Relative effectiveness of warfarin and aspirin in preventing recurrent ischemic stroke or death over 2 years was compared based on NT-proBNP concentrations. RESULTS: About 95% of 1028 patients with assays had NT-proBNP below 750 pg/mL, and among them, no evidence for treatment effect modification was evident. For 49 patients with NT-proBNP >750 pg/mL, the 2-year rate of events per 100 person-years was 45.9 for the aspirin group and 16.6 for the warfarin group, whereas for 979 patients with NT-proBNP ≤750 pg/mL, rates were similar for both treatments. For those with NT-proBNP >750 pg/mL, the hazard ratio was 0.30 (95% confidence interval: 0.12-0.84; P=0.021) significantly favoring warfarin over aspirin. A formal test for interaction of NT-proBNP with treatment was significant (P=0.01). CONCLUSIONS: For secondary stroke prevention, elevated NT-proBNP concentrations may identify a subgroup of ischemic strokepatients without known atrial fibrillation, about 5% based on the current study, who may benefit more from anticoagulants than antiplatelet agents. Clinical Trial Registration- This trial was not registered because enrollment began before 2005.
Authors: A M Mäkikallio; T H Mäkikallio; J T Korpelainen; O Vuolteenaho; J M Tapanainen; K Ylitalo; K A Sotaniemi; H V Huikuri; V V Myllylä Journal: Stroke Date: 2005-03-31 Impact factor: 7.914
Authors: Shunichi Homma; John L P Thompson; Patrick M Pullicino; Bruce Levin; Ronald S Freudenberger; John R Teerlink; Susan E Ammon; Susan Graham; Ralph L Sacco; Douglas L Mann; J P Mohr; Barry M Massie; Arthur J Labovitz; Stefan D Anker; Dirk J Lok; Piotr Ponikowski; Conrado J Estol; Gregory Y H Lip; Marco R Di Tullio; Alexandra R Sanford; Vilma Mejia; Andre P Gabriel; Mirna L del Valle; Richard Buchsbaum Journal: N Engl J Med Date: 2012-05-02 Impact factor: 91.245
Authors: Kristen K Patton; Patrick T Ellinor; Susan R Heckbert; Robert H Christenson; Christopher DeFilippi; John S Gottdiener; Richard A Kronmal Journal: Circulation Date: 2009-10-19 Impact factor: 29.690
Authors: Steven R Levine; Robin L Brey; Barbara C Tilley; J L P Thompson; Ralph L Sacco; Robert R Sciacca; A Murphy; Yimeng Lu; Teresa M Costigan; Candi Rhine; Bruce Levin; Douglas A Triplett; J P Mohr Journal: JAMA Date: 2004-02-04 Impact factor: 56.272
Authors: Karl Georg Haeusler; Klaus Gröschel; Martin Köhrmann; Stefan D Anker; Johannes Brachmann; Michael Böhm; Hans-Christoph Diener; Wolfram Doehner; Matthias Endres; Christian Gerloff; Hagen B Huttner; Manfred Kaps; Paulus Kirchhof; Darius Günther Nabavi; Christian H Nolte; Waltraud Pfeilschifter; Burkert Pieske; Sven Poli; Wolf Rüdiger Schäbitz; Götz Thomalla; Roland Veltkamp; Thorsten Steiner; Ulrich Laufs; Joachim Röther; Rolf Wachter; Renate Schnabel Journal: Clin Res Cardiol Date: 2018-04-27 Impact factor: 5.460
Authors: Shadi Yaghi; Yeseon P Moon; Consuelo Mora-McLaughlin; Joshua Z Willey; Ken Cheung; Marco R Di Tullio; Shunichi Homma; Hooman Kamel; Ralph L Sacco; Mitchell S V Elkind Journal: Stroke Date: 2015-04-23 Impact factor: 7.914
Authors: Mary Cushman; Suzanne E Judd; Virginia J Howard; Brett Kissela; Orlando M Gutiérrez; Nancy S Jenny; Ali Ahmed; Evan L Thacker; Neil A Zakai Journal: Stroke Date: 2014-04-22 Impact factor: 7.914
Authors: Shadi Yaghi; Amelia K Boehme; Rebecca Hazan; Eldad A Hod; Alberto Canaan; Howard F Andrews; Hooman Kamel; Randolph S Marshall; Mitchell S V Elkind Journal: J Stroke Cerebrovasc Dis Date: 2015-10-21 Impact factor: 2.136